Allogene Therapeutics
Peng Cui has a strong background in the pharmaceutical industry, with experience in various roles and companies. Cui most recently worked at Allogene Therapeutics as the Associate Director and Head of QC Chemistry/Biochemistry Lab and Raw Material Management. Prior to that, Cui spent several years at Regeneron Pharmaceuticals, Inc. as a Senior Manager in Quality Control. Cui also worked at AMRI as a Senior Research Scientist and at UCLA as a Research Associate.
Peng Cui holds a Ph.D. degree in Organic/Medicinal Chemistry from the University of Virginia. Prior to that, they completed their Bachelor of Science degree in Chemistry at Peking University.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.